Exenatide
Also known as: Byetta, Bydureon, Exendin-4
Popular For
Diabetes management, weight loss, glucose control
Key Facts: Exenatide
- Category
- Weight Loss
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Type 2 diabetes
- Administration
- Subcutaneous injection
- Typical Dose
- 5-10 mcg twice daily or 2 mg weekly
- Frequency
- Twice daily (IR) or once weekly (ER)
- Evidence Level
- FDA Approved
- Duration
- Long-term / chronic use
Mechanism of Action
Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite.
Research Summary
First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels.
Dosing Information
Typical Dosingⓘ
Community experience
5-10 mcg twice daily or 2 mg weekly
5-10 mcg (IR) or 2 mg (ER)
Twice daily (IR) or once weekly (ER)
First GLP-1 approved. Byetta (twice daily) or Bydureon (weekly). Must be injected.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
5-10 mcg twice daily (Byetta)
2mg weekly (Bydureon)
Duration
Long-term / chronic use
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (common)
- ●Vomiting
- ●Diarrhea
- ●Dizziness
- ●Hypoglycemia
- ●Injection site reactions
- ●Pancreatitis (BOXED WARNING)
- ●Acute kidney injury
- ●FDA approved (Byetta, Bydureon)
References
Related Peptides
Peptides commonly compared with Exenatide or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossDulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.
Weight LossLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Exenatide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.